Abstract: Nucleic acids encoding Parvoviral Rep proteins with a mutated nuclear localization signal (NLS) are provided. Also provided is a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein with a mutated zinc finger domain and a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein comprising an amino acid mutation at position 43, 57, 79, 97, 120, 179, 305, 484, 493 or 571 with reference to SEQ ID NO: 2. Nucleic acid constructs and cells, such as insect cells, comprising the nucleic acids are provided as well as a method for producing a recombinant Parvoviral virion using the nucleic acids.
Type:
Grant
Filed:
January 5, 2018
Date of Patent:
September 3, 2019
Assignee:
Uniqure IP B.V.
Inventors:
Yvet Noordman, Jacek Lubelski, Andrew Christian Bakker
Abstract: The present invention relates to the field of medicine and virology. An attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof are provided, which can be used for the prevention and/or treatment of an infectious disease. In addition, the present invention relates to an attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof, which can be used for the treatment of oncological diseases.
Type:
Grant
Filed:
November 3, 2016
Date of Patent:
August 27, 2019
Assignee:
PHARMENTERPRISES BIOTECH Limited Liability Company
Inventors:
Andrei Yurievich Egorov, Boris Ferko, Artem Alexandrovich Krokhin, Yulia Romanovna Romanova
Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
August 27, 2019
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
William Jacobs, Jr., Pablo A. Gonzalez-Munoz, Betsy Herold, Christopher Petro
Abstract: The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked to Pseudomonas exotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of HSV2 and/or HIV-1.
Abstract: In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO.
Abstract: Discloses are a method for detecting Norovirus using a Norovirus animal model, a method for screening an antivial agent against Norovirus, and a composition for neutralizing the infection with an enteric virus, containing concanavalin A as an active ingredient, so that the method for detecting Norovirus can allow the distinction between infectious Norovirus and non-infectious Norovirus, and the composition can neutralize a virus causing food poisoning.
Type:
Grant
Filed:
May 10, 2016
Date of Patent:
August 13, 2019
Assignees:
INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY, KOREA BASIC SCIENCE INSTITUTE
Abstract: It is an object of the present invention to provide utilization of a UCA1 gene that is a host regulatory factor that enhances replication and/or propagation of a vaccinia virus, in order to effectively carry out cancer virotherapy using the vaccinia virus. The present invention relates to: a method for predicting and evaluating the cancer therapeutic effects of a vaccinia virus, which comprises measuring the expression of a UCA1 gene in the cancer cells of a cancer patient, and then predicting that a vaccinia virus exhibits cancer therapeutic effects on the patient, when the UCA1 gene has been expressed therein; and a vaccinia virus into which a UCA1 gene has been expressibly introduced.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
August 6, 2019
Assignee:
National University Corporation Tottori University
Abstract: The invention generally relates to recombinant human cytomegalovirus (CMV) gB proteins and immunogenic fragments thereof, which do not comprise a transmembrane (TM) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gB, and/or adhesion of the monomeric trimer of gB to the host cell.
Type:
Grant
Filed:
December 7, 2015
Date of Patent:
July 30, 2019
Assignee:
GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventors:
Andrea Carfi, Sumana Chandramouli, Ethan C. Settembre
Abstract: The invention relates to a protein comprising a plurality of conserved peptide sequences, or variants thereof, wherein at least one of the conserved sequences is conserved across all four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4, and wherein the conserved sequences comprise at least part of a sequence of one or more non-structural proteins of the dengue virus serotypes. The invention further relates to associated peptides, compositions, nucleic acids, viral vectors, virus-like particles, use, prime boost vaccination kits, agents and methods.
Type:
Grant
Filed:
May 11, 2016
Date of Patent:
July 16, 2019
Assignee:
Oxford University Innovation Limited
Inventors:
Arturo Reyes-Sandoval, Cesar Lopez-Camacho, Joshua Blight
Abstract: The present disclosure provides certain combinations of immunogenic compositions against HSV-2 and antiviral therapy. The vaccines can be used therapeutically and/or prophylactically.
Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
July 9, 2019
Assignees:
Memorial Sloan Kettering Cancer Center, Cornell University
Inventors:
Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
Abstract: Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.
Type:
Grant
Filed:
March 25, 2016
Date of Patent:
June 25, 2019
Assignee:
The Children's Hospital of Philadelphia
Inventors:
John Fraser Wright, Guang Qu, Bernd Hauck, Katherine A. High
Abstract: Attenuated isolates of the Arkansas serotype of infectious bronchitis virus (IBV), including the IBV isolate ArkGA p60 deposited at the ATCC under Patent Designation PTA-123783, and compositions thereof are presented. Methods for administering the isolates or compositions as vaccines to the prevent virulent IBV infection in birds of the order Galliformes are also presented.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
June 25, 2019
Assignee:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Abstract: Embodiments of nucleic acids comprise a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. Also provided is a live-attenuated recombinant Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter.
Type:
Grant
Filed:
March 22, 2018
Date of Patent:
June 25, 2019
Assignee:
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
Abstract: The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
Type:
Grant
Filed:
December 13, 2017
Date of Patent:
June 18, 2019
Assignee:
BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Inventors:
Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz, Aemro Kassa
Abstract: CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.
Type:
Grant
Filed:
September 1, 2017
Date of Patent:
June 11, 2019
Assignee:
Oregon Health & Science University
Inventors:
Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli
Abstract: The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis B virus in individuals in need thereof.
Abstract: Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension.
Type:
Grant
Filed:
November 14, 2017
Date of Patent:
June 11, 2019
Assignees:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, HEALTH RESEARCH, INCORPORATED